Skip to main content
. 2022 Oct 11;12(10):1376. doi: 10.3390/brainsci12101376

Figure 5.

Figure 5

Isofraxidin alleviates CUMS-induced increase of immobility duration in FST and TST. (A) Duration of immobility in FST. (B) Total immobility time in TST. Data are presented as means ± SEM (n = 10). The Control group was CUMS-free mice administered with normal saline. CUMS group was CUMS mice. Significance was analyzed by one-way ANOVA followed by the Bonferroni correction. ## p < 0.01, compared with the control group. ** p < 0.01, compared with CUMS group.